MedTrace Logo

A Pharmacokinetic and Bioavailability Study of Mannitol for Inhalation Using Normal Subjects

NCT00446771 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2007-03-13

No results posted yet for this study

Summary

The study has an open-label, randomized, crossover design, in which each subject will receive mannitol powder for inhalation using a dry powder inhaler with and without premedication with a bronchodilator, mannitol powder for inhalation in capsules administered orally, and mannitol in a commercial formulation designed for intravenous use.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Mannitol

Sponsors & Collaborators

  • Syntara

    lead INDUSTRY

Principal Investigators

  • Andrew Humberstone · Nucleus Networks

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Completion
2006-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00446771 on ClinicalTrials.gov